• About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact
  • About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact
U.S. strikes $230 million deal for over-the-counter Covid tests

U.S. strikes $230 million deal for over-the-counter Covid tests

The Biden administration announced a $230 million deal to ramp up production of the country’s first over-the-counter, at-home Covid-19 test. “These are over-the-counter, self-performed test kits that can detect Covid with roughly 95 percent accuracy within 15 minutes,” Andy Slavitt, the White House senior adviser for Covid-19 response, told reporters on Monday.
Read More
A fast, at-home coronavirus test will be available to Americans this year

A fast, at-home coronavirus test will be available to Americans this year

The White House announced Monday it is buying 8.5 million rapid coronavirus tests that can be taken at home without a prescription and that yield immediate results. The $231.8 million contract will allow the Australian company Ellume, which manufacturers the tests, to quickly scale up its production and create a manufacturing facility in the United States.Once running, […]
Read More
U.S. Cuts $231 Million Deal To Provide 15-Minute COVID-19 At-Home Tests

U.S. Cuts $231 Million Deal To Provide 15-Minute COVID-19 At-Home Tests

The Biden administration has made a $231.8 million deal with an Australian company to boost availability of the first at-home rapid test for the coronavirus which causes COVID-19 that is available without a prescription. The test, made by Ellume, can send results to a smartphone within 15 minutes of receiving a sample.
Read More
US Government signs deal to produce Australian COVID-19 Home Test kits

US Government signs deal to produce Australian COVID-19 Home Test kits

Ellume Founder, CEO and Managing Director Dr Sean Parsons spoke with David Koch on Channel 7’s Sunrise program last week to discuss Ellume’s US$231.8 million contract with the U.S. Government to establish a U.S. manufacturing facility and deliver 8.5 million COVID-19 home tests across the U.S in the coming months.
Read More
Ellume Announces $231.8 Million Agreement with the U.S. Government

Ellume Announces $231.8 Million Agreement with the U.S. Government

The contract includes the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. Government’s pandemic response The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed; The investment extends Ellume’s engagement with the U.S. government following the NIH […]
Read More
FDA authorizes Ellume COVID-19 Home Test as First Over-the-Counter Fully At-Home Diagnostic Test

FDA authorizes Ellume COVID-19 Home Test as First Over-the-Counter Fully At-Home Diagnostic Test

Proven performance in adults and children, with and without symptoms Highlights FDA grants Emergency Use Authorization for Ellume COVID-19 Home Test for non-prescription home use in symptomatic and asymptomatic individuals The test demonstrated 96% accuracy in a multi-site US clinical study of both adults and children 2 years and above Ellume is ramping up manufacture, […]
Read More
Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study

Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study

Highlights Ellume submits Emergency Use Authorization to the U.S. Food and Drug Administration for the Ellume COVID-19 home test Clinical study demonstrated overall sensitivity of 95% and specificity of 97% Clinically validated for use in symptomatic and asymptomatic users ages 2 years and above Independently run, simulated home-use clinical study of 198 subjects Ellume is […]
Read More

ABC Radio “The Money” Interview with Ellume CEO, Dr Sean Parsons

29 October 2020, Richard Aedy Ellume Founder, CEO and Managing Director Dr Sean Parsons was interviewed by ABC Radio’s Richard Aedy on The Money program about how the company is scaling up its Brisbane manufacturing facilities as part of a US push to develop rapid COVID-19 testing technology. This interview originally appeared on ABC Radio […]
Read More
Ellume enlists Bosch Australia to automate manufacturing for high-performance COVID-19 Test

Ellume enlists Bosch Australia to automate manufacturing for high-performance COVID-19 Test

Highlights Ellume will collaborate with Bosch to create state-of-the-art automated production lines, to scale up manufacturing volumes of COVID-19 and other diagnostic tests. Bosch capabilities will build resilience and innovation into the local Ellume manufacturing processes. Bosch global automation and manufacturing know-how harnessed to ensure successful industrialisation of Ellume COVID-19 consumable test. New Ellume manufacturing […]
Read More

10 News First reports Ellume’s $42M NIH funding for rapid COVID test

8 October 2020, Samantha Butler Ellume Founder, CEO and Managing Director Dr Sean Parsons was recently interviewed by 10 News First Queensland’s Samantha Butler on the successful awarding of $42m from the US NIH to Ellume to scale up and fast track the production of its COVID-19 diagnostic tests. This interview originally appeared on 10 […]
Read More
Page 1 of 3123
Recent Posts
  • QIAGEN receives U.S. FDA emergency use authorization for rapid portable SARS-CoV-2 antigen test
  • Push to allow at-home COVID tests in Australia
  • Why Aussie startup Ellume’s home-testing tech should help us in the COVID-19 recovery, but can’t
  • An Australian firm producing home COVID-19 tests for the US market has called on the federal government to reconsider its ban
  • Rapid COVID-19 Testing Device, Sunrise Interview with Ellume CEO Dr Sean Parsons
Archives
Categories
Business
Scroll
ellume logo white
Menu

Home
About Us
COVID-19 Response
Consumer Products
Professional Products
Global Public Health Solutions
Our Tech
News

Quick Links

Contact Us
Terms of Use
Privacy Policy
Whistleblower Policy

Some Ellume products are pending regulatory clearance. © Ellume Limited 2021
ABN 13 141 767 660